Acute graft-versus-host disease
ICD-10 D89.810 is a billable code used to indicate a diagnosis of acute graft-versus-host disease.
Acute graft-versus-host disease (aGVHD) is a serious complication that can occur after allogeneic hematopoietic stem cell transplantation (HSCT), where the donor's immune cells attack the recipient's tissues. This condition typically manifests within 100 days post-transplant and is characterized by a range of symptoms including skin rash, diarrhea, liver dysfunction, and hematologic abnormalities. The pathophysiology involves the activation of donor T-lymphocytes that recognize the recipient's tissues as foreign, leading to an inflammatory response. The severity of aGVHD is classified into grades I to IV based on the extent of organ involvement and the severity of symptoms. Management strategies include immunosuppressive therapies, such as corticosteroids, to mitigate the immune response and prevent further tissue damage. Early recognition and treatment are crucial to improve outcomes and reduce morbidity associated with this condition.
Detailed documentation of transplant history, symptoms, and treatment response is essential.
Patients presenting with skin rashes, gastrointestinal symptoms, or liver dysfunction post-transplant.
Ensure clear differentiation between acute and chronic forms of graft-versus-host disease.
Comprehensive surgical notes and post-operative care documentation are critical.
Monitoring patients for signs of aGVHD after hematopoietic stem cell transplantation.
Collaboration with hematology for accurate coding and management of complications.
Used to evaluate for aGVHD in patients with hematologic malignancies post-transplant.
Document indications for biopsy and findings.
Hematology specialists should ensure correlation with clinical symptoms.
Common symptoms include skin rash, diarrhea, liver dysfunction, and fever. Symptoms typically arise within 100 days post-transplant.
